Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biotechnology firm Globavir Biosciences is planning to develop its lead drug candidate, GBV006, to treat the current Ebola Virus outbreak in West Africa.
Subscribe to our email newsletter
The company, which has the worldwide exclusive license to develop and market GBV006, is seeking approval for the use of the product, a combination of Food and Drug Administration (FDA) approved drugs, through an established use regulatory pathway.
The discovery of the use of GBV006 to treat infectious diseases was made at Stanford University School of Medicine.
The component drugs of GBV006 have showed efficacy against experimental models of Ebola infection at dosages already approved and well-tolerated by patients.
The drug candidate is effective at low micromolar concentrations against Ebola in vitro.
Globavir CEO Shalabh Gupta said the situation in West Africa is dire, and there is an immediate need for drugs able to reduce the impact of Ebola infection.
"By repurposing a combination of approved drugs to treat Ebola virus, Globavir has the potential to overcome many hurdles regarding safety and supply of experimental therapies," Gupta said.
"We hope to quickly form partnerships to distribute this potentially life-saving drug to those who need it most."
The company’s antiviral therapeutic platform has multiple drugs under development, which were discovered, tested and licensed from Stanford University and is currently evaluating several drug combinations for Ebola treatment.